Please Wait.....
Report
Global Influenza Vaccine Market Report and Forecast 2023-2031
Market Report I 2023-05-08 I 147 Pages I EMR Inc.
Global Influenza Vaccine Market Report and Forecast 2023-2031
Global Influenza Vaccine Market Outlook
The global influenza vaccine market value was USD 5.9 billion in 2022, driven by the increased awareness about the health risks associated with influenza across the globe. The market size is anticipated to grow at a CAGR of 7.3% during the forecast period of 2023-2031 to achieve a value of USD 11.1 billion by 2031.
Influenza Vaccine: Introduction
Influenza vaccines, also known as flu shots, are formulated to protect against the influenza virus, a contagious respiratory illness with varying severity levels. Influenza vaccines are updated annually, as the virus mutates rapidly, and different strains circulate each flu season. The vaccines aim to stimulate an immune response by using inactivated or weakened viruses, or specific viral components like recombinant proteins or viral vectors, to mimic the natural infection.
Flu vaccines are usually trivalent or quadrivalent, meaning they protect against three or four strains of the virus, respectively. The World Health Organization (WHO) recommends the strains to be included in the vaccine each year, based on global surveillance data and predictions about the most prevalent strains for the upcoming flu season.
Influenza vaccination is recommended for most individuals, particularly those at higher risk of developing severe complications, such as the elderly, young children, pregnant women, and individuals with chronic health conditions. The vaccines are typically administered via an injection in the upper arm, but nasal spray vaccines are also available for specific age groups. While flu vaccines do not guarantee complete protection from the virus, they significantly reduce the risk of infection and minimize the severity of illness for those who contract the flu. In addition, widespread vaccination contributes to herd immunity, helping to protect vulnerable populations who may not be able to receive the vaccine themselves.
Influenza Vaccine Market Scenario
The global influenza vaccine market is witnessing significant growth as a result of increased awareness about the health risks associated with influenza and the importance of vaccination in preventing flu-related complications. Influenza, or the flu, is a highly contagious respiratory illness caused by the influenza virus, with varying degrees of severity. Annual vaccination is recommended as the virus mutates rapidly, leading to different strains circulating each flu season.
Influenza vaccines aim to stimulate an immune response using inactivated or weakened viruses or specific viral components to mimic a natural infection. These vaccines are typically trivalent or quadrivalent, meaning they protect against three or four strains of the virus, respectively. The World Health Organization (WHO) recommends the strains to be included in the vaccines each year based on global surveillance data and predictions about the most prevalent strains for the upcoming flu season.
The market's growth is driven by factors such as expanding target populations for vaccination, technological advancements in vaccine development, and increasing investments in research and development.
North America: The largest market for influenza vaccines, driven by factors such as advanced healthcare infrastructure, high vaccination rates, and significant investments in research and development.
Europe: The second-largest market, with increasing demand for flu vaccines due to a growing aging population, a supportive regulatory framework, and an expanding healthcare sector.
Asia-Pacific: Expected to witness the highest growth rate due to factors such as a rapidly growing population, increasing awareness of influenza and vaccination, and growing investments in healthcare infrastructure and research.
Influenza Vaccine Market Segmentations
Market Breakup by Vaccine Type
- Quadrivalent
- Trivalent
Market Breakup by Technology
- Egg Based
- Cell Based
Market Breakup by Age Group
- Pediatric
- Adult
Market Breakup by Route of Administration
- Injection
- Nasal Spray
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Government and Institution Supply
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Trends in the Influenza Vaccine Market
Some key trends of the market are as follows:
- Increasing awareness of influenza and the importance of vaccination: The rising awareness of the health risks associated with influenza and the significance of vaccination in preventing flu-related complications has led to increased demand for flu vaccines.
- Expanding target populations for vaccination: Expanded vaccination recommendations, including wider age groups and high-risk populations, have contributed to the growth of the influenza vaccine market.
- Technological advancements in vaccine development: Innovations in vaccine development, such as cell-based and recombinant technologies, have improved the efficacy and production efficiency of influenza vaccines, further driving market growth.
Influenza Vaccine: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AstraZeneca plc
- Biodiem Limited
- CSL Limited
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche AG
- Gamma Vaccines Pty Ltd
- GlaxoSmithKline Plc.
- Merck and Co., Inc.
- Pfizer Inc.
- Sanofi S.A.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Influenza Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Influenza Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Influenza Epidemiology (2016-2031)
5.3 Europe Influenza Epidemiology (2016-2031)
5.4 Asia-Pacific Influenza Epidemiology (2016-2031)
5.5 Latin America Influenza Epidemiology (2016-2031)
5.6 Middle East & Africa Influenza Epidemiology (2016-2031)
6 Global Influenza Vaccine Market Overview
6.1 Global Influenza Vaccine Market Historical Value (2016-2022)
6.2 Global Influenza Vaccine Market Forecast Value (2023-2031)
7 Global Influenza Vaccine Market Landscape
7.1 Global Influenza Vaccine Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Influenza Vaccine Product Landscape
7.2.1 Analysis by Vaccine Type
7.2.2 Analysis by Technology
7.2.3 Analysis by Age Group
8 Influenza Vaccine Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Influenza Vaccine Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Influenza Vaccine Market Segmentation
11.1 Global Influenza Vaccine Market by Vaccine Type
11.1.1 Market Overview
11.1.2 Quadrivalent
11.1.3 Trivalent
11.2 Global Influenza Vaccine Market by Technology
11.2.1 Market Overview
11.2.2 Egg Based
11.2.3 Cell Based
11.3 Global Influenza Vaccine Market by Age Group
11.3.1 Market Overview
11.3.2 Pediatric
11.3.3 Adult
11.4 Global Influenza Vaccine Market by Route of Administration
11.4.1 Market Overview
11.4.2 Injection
11.4.3 Nasal Spray
11.5 Global Influenza Vaccine Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Government and Institution Supply
11.5.4 Others
11.6 Global Influenza Vaccine Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Influenza Vaccine Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Influenza Vaccine Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Influenza Vaccine Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Influenza Vaccine Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Influenza Vaccine Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 AstraZeneca plc
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Biodiem Limited
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 CSL Limited
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Emergent BioSolutions Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 F. Hoffmann-La Roche AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Gamma Vaccines Pty Ltd
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 GlaxoSmithKline Plc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Merck and Co., Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Pfizer Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Sanofi S.A.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Others
24 Global Influenza Vaccine Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security